UPDATE: Four Recent Milestones for Diagnostics Company SpectraScience (SCIE)

Posted by Laura Swartz

September 15, 2016 at 2:14 PM

  • Up to 80% of colorectal biopsies performed are subsequently identified as normal, non-cancerous tissue. Incorporating an optical biopsy, such as WavSTAT4, before performing an invasive physical biopsy reduces risks to patients by eliminating many unnecessary procedures and may lead to a healthcare cost savings of over $1 billion in the U.S. alone.

  • SpectraScience is working to diagnose “pre-cancers”—suspect tissue or areas in the body before it becomes cancerous. Tissue that WavSTAT4 finds to be precancerous (or cancerous) returns a red “suspect” icon. Unlike the traditional method of visual inspection, there is no ambiguity to the result and no need for physician interpretation.

  • Major 2016 corporate developments include a strategic acquisition, research publication, and development of an international sales infrastructure enabling the start of device sales in the Middle East.

Read More

Topics: SpectraScience

NEW RESEARCH: 48-page Report Available on Diagnostics Company SpectraScience (SCIE)

Posted by Laura Swartz

August 6, 2015 at 12:05 PM

Crystal Research Associates announces the publication of an Executive Informational Overview (EIO) on SpectraScience, Inc. (SCIE-OTC), a company commercializing advanced, minimally invasive diagnostic products. The 48-page EIO, which details SpectraScience's business, technology and product development, clinical studies, manufacturing, market opportunities, competition, and more, is available for download below.

Read More

Topics: SpectraScience

Content not found
Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic